Influence Of FOLFOX4Combined1-MT On The Surface Molecular Of Dendritic Cells In The Spleen Of Mice Of Gastric Cancer

Objective The present study was designed to detect the inhibition effect of FOLFOX4combined1-MT on transplant gastric carcinoma growth in mice subcutaneous and the effect of FOLFOX4combined1-MT on the expression of Indoleamine-2,3-dioxygenase (IDO) in gastric cancer tissue and the surface molecules of dendritic cells (DC) of the spleen in the gastric cancer mice.Methods The mice gastric cancer cells MFC were transfected with IDO gene recombinant plasmid by lipofectamine method. The IDOmRNA was highly expressed in pcDNA3.1-IDO cells. Murine model of gastric cancer was established. Tumor-bearing mice was divided into6gmups: MFC non-transfected group, pcDNA3.1transfected group, pcDNA3.1-IDO transfected group,1-MT-pcDNA3.1-IDO treatment group, FOLFOX4-pcDNA3.1-IDO treatment group and FOLFOX4+1-MT-pcDNA3.1-IDO treatment group. We can observe the mice tumor cases, the differences of tumor weight, and then detect the expression of IDO in tumor tissues by immunohistochemical, the expression of IDOmRNA of the spleen organization of tumor-bearing mice by RT-PCR, the expression of CD11c, and CD86, and CD80, and Major histocompatibility Antigen complex Ⅱ (MHC-Ⅱ) in the surface of Dendritic Cells of the spleen of tumor-bearing mice by Flow cytometry.Results Compared with MFC non-transfected group and pcDNA3.1transfected group, the tumor on pcDNA3.1-IDO transfected group grows faster, the weight of tumor increases significantly(P<0.05). Compared with pcDNA3.1-IDO transfected group, the weight of tumor on1-MT-pcDNA3.1-IDO treatment group, FOLFOX4-pcDNA3.1-IDO treatment group and FOLFOX4+1-MT-pcDNA3.1-IDO treatment group decreases significantly(P<0.05). The tumor inhibitory rates were8.91%,80.20%,86.13%respectively. There were significant differences between them(P<0.05),Compared with1-MT-pcDNA3.1-IDO treatment group and FOLFOX4-pcDNA3.1-IDO treatment group, the weight of tumor on FOLFOX4+1-MT-pcDNA3.1-IDO treatment group decreases significantly(P<0.05). IDO expression in tumor tissues:in1-MT-pcDNA3.1-IDO treatment group, FOLFOX4-pcDNA3.1-IDO treatment group and FOLFOX4+1-MT-pcDNA3.1-IDO treatment group, cancer cells were less color, especially in the FOLFOX4+1-MT-pcDNA3.1-IDO treatment group there was even no brown color cells; the gastric cancer cells in MFC non-transfected group, pcDNA3.1transfected group, pcDNA3.1-IDO transfected group were more, which were arranged in sheets, much larger, colored extensively, and more colored granules. Compared with MFC non-transfected group and pcDNA3.1transfected group, the expression of IDOmRNA of pcDNA3.1-IDO transfected group increases significantly(P<0.05). The expression of IDOmRNA of MFC non-transfected groupand pcDNA3.1transfected group are not significantly different (P>0.05)。Compared with the pcDNA3.1-IDO transfected group, the expression of IDOmRNA of1-MT-pcDNA3.1-IDO treatment group, FOLFOX4-pcDNA3.1-IDO treatment group and FOLFOX4+1-MT-pcDNA3.1-IDO treatment group reduces significantly (P<0.05). Compared with FOLFOX4+1-MT-pcDNA3.1-IDO treatment group, the expression of IDOmRNA of1-MT-pcDNA3.1-IDO treatment group and FOLFOX4-pcDNA3.1-IDO treatment group increases significantly (P<0.05). Compared with the pcDNA3.1-IDO transfected group, the number of DC in the spleen of MFC non-transfected group, pcDNA3.1transfected group and1-MT-pcDNA3.1-IDO treatment group increases Slightly. Compared with the pcDNA3.1-IDO transfected group, the number of DC in the spleen of FOLFOX4-pcDNA3.1-IDO treatment group and FOLFOX4+1-MT-pcDNA3.1-IDO t increases significantly (P<0.05). Compared with the FOLFOX4+1-MT-pcDNA3.1-IDOt, the number of DC in the spleen of1-MT-pcDNA3.1-IDO treatment group, FOLFOX4-pcDNA3.1-IDO treatment group reduces Slightly.Compared with the pcDNA3.1-IDO transfected group the surface molecule including CD86, CD80and MHC-Ⅱ of DC of the spleen of MFC non-transfected group, pcDNA3.1transfected group,1-MT-pcDNA3.1-IDO treatment group, FOLFOX4-pcDNA3.1-IDO treatment group and FOLFOX4+1-MT-pcDNA3.1-IDO treatment group increases significantly (P<0.05). Compared with the FOLFOX4+1-MT-pcDNA3.1-IDO treatment group, the surface molecule including CD86, CD80and MHC-Ⅱ of DC of the spleen of1-MT-pcDNA3.1-IDO treatment group and FOLFOX4-pcDNA3.1-IDO treatment group reduces significantly (P<0.05).Conclusions FOLFOX4combined1-MT inhibites the transplant tumor growth in mice subcutaneous, down-regulated the Indoleamine-2,3-dioxygenase (IDO) expression in gastric cancer tissue, reduces the expression of IDOmRNA of the spleen organization of tumor-bearing mice, increases the activity of dendritic cells in the spleen of tumor-bearing mice and improves the ability of the body to resist cancer.